Plasma homocysteine is a determinant of tissue necrosis factor-α in hypertensive patients

Biomedicine and Pharmacotherapy

Volumn 62, Issue 6, 2008, Pages 360-365

  Bogdanski, P ^a   Pupek Musialik, D ^a   Dytfeld, J ^a   Lacinski, M ^a   Jablecka, A ^a   Jakubowski, H ^b,c  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^b INSTITUTE OF BIOORGANIC CHEMISTRY   (Poland)

^c RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

Author keywords

Homocysteine; Hypertension; TNF

Indexed keywords

C REACTIVE PROTEIN; HOMOCYSTEINE; INTERLEUKIN 6; LIPID; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; CONTROLLED STUDY; CORRELATION ANALYSIS; ESSENTIAL HYPERTENSION; FEMALE; HEART INFARCTION; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; OBESITY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; STROKE;

ADULT; C-REACTIVE PROTEIN; FEMALE; HOMOCYSTEINE; HUMANS; HYPERTENSION; INFLAMMATION; INTERLEUKIN-6; LIPIDS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; OBESITY; PREDICTIVE VALUE OF TESTS; REGRESSION ANALYSIS; STROKE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 46049092171     PISSN: 07533322     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biopha.2007.10.019     Document Type: Article

References (40)

1. McCully K.S. Vascular pathology of homocysteinemia: implications for the pathogenesis of arteriosclerosis. Am J Pathol 56 (1969) 111-128
2. Wald D.S., Law M., and Morris J.K. Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis. Br Med J 325 (2002) 1202-1209
3. Lentz S.R. Mechanisms of homocysteine-induced atherothrombosis. J Thromb Haemost 3 (2005) 1646-1654
4. Jakubowski H. Molecular basis of homocysteine toxicity in humans. Cell Mol Life Sci 61 (2004) 470-487
5. Undas A., Brozek J., Jankowski M., Siudak Z., Szczeklik A., and Jakubowski H. Plasma homocysteine affects fibrin clot permeability and resistance to lysis in human subjects. Arterioscler Thromb Vasc Biol 26 (2006) 1397-1404
6. Gori A.M., Corsi A.M., Fedi S., Gazzini A., Sofi F., Bartali B., et al. A proinflammatory state is associated with hyperhomocysteinemia in the elderly. Am J Clin Nutr 82 (2005) 335-341
7. Winder B., Leblhuber F., Frick B., Laich A., Artner-Dworzak E., and Fuchs D. Moderate hyperhomocysteinaemia and immune activation in Parkinson's disease. J Neurol Transm 109 (2002) 1445-1452
8. Jakubowski H. Anti-N-homocysteinylated protein autoantibodies and cardiovascular disease. Clin Chem Lab Med 43 (2005) 1011-1014
9. Libby P. Inflammation in atherosclerosis. Nature 420 (2002) 868-874
10. Niskanen L., Laaksonen D.E., Nyyssonen K., Punnonen K., Valkonen V.P., Fuentes R., et al. Inflammation, abdominal obesity, and smoking as predictors of hypertension. Hypertension 44 (2004) 859-865
11. Matsuzawa Y. Adipocytokines and metabolic syndrome. Semin Vasc Med 5 (2005) 34-39
12. Festa A., D'Agostino Jr. R., Williams K., Karter A.J., Mayer-Davis E.J., Tracy R.P., et al. The relation of body fat mass and distribution to markers of chronic inflammation. Int J Obes Relat Metab Disord 25 (2001) 1407-1415
13. Aronson D., Bartha P., Zinder O., Kerner A., Markiewicz W., Avizohar O., et al. Obesity is the major determinant of elevated C-reactive protein in subjects with the metabolic syndrome. Int J Obes Relat Metab Disord 28 (2004) 674-679
14. Frane J. All possible subsets regression. In: Dixon W.J., Brown M.B., Engelman L., and Jennrich R.I. (Eds). BMPD statistical software manual (1990), University of California Press, Berkeley 993
15. Lim U., and Cassano P.A. Homocysteine and blood pressure in the Third National Health and Nutrition Examination Survey, 1988-1994. Am J Epidemiol 156 (2002) 1105-1113
16. Nygard O., Vollset S.E., Refsum H., Stensvold I., Tverdal A., Nordrehaug J.E., et al. Total plasma homocysteine and cardiovascular risk profile. The Hordaland Homocysteine Study. J Am Med Assoc 274 (1995) 1526-1533
17. Sutton-Tyrrell K., Bostom A., Selhub J., and Zeigler-Johnson C. High homocysteine levels are independently related to isolated systolic hypertension in older adults. Circulation 96 (1997) 1745-1749
18. van Dijk R.A., Rauwerda J.A., Steyn M., Twisk J.W., and Stehouwer C.D. Long-term homocysteine-lowering treatment with folic acid plus pyridoxine is associated with decreased blood pressure but not with improved brachial artery endothelium-dependent vasodilation or carotid artery stiffness: a 2-year, randomized, placebo-controlled trial. Arterioscler Thromb Vasc Biol 21 (2001) 2072-2079
19. Sundstrom J., Sullivan L., D'Agostino R.B., Jacques P.F., Selhub J., Rosenberg I.H., et al. Plasma homocysteine, hypertension incidence, and blood pressure tracking: the Framingham Heart Study. Hypertension 42 (2003) 1100-1105
20. Kerkeni M., Tnani M., Chuniaud L., Miled A., Maaroufi K., and Trivin F. Comparative study on in vitro effects of homocysteine thiolactone and homocysteine on HUVEC cells: evidence for a stronger proapoptotic and proinflammative homocysteine thiolactone. Mol Cell Biochem 291 (2006) 119-126
21. Su S.J., Huang L.W., Pai L.S., Liu H.W., and Chang K.L. Homocysteine at pathophysiologic concentrations activates human monocyte and induces cytokine expression and inhibits macrophage migration inhibitory factor expression. Nutrition 21 (2005) 994-1002
22. Albert K., Balkau B., Standl E., Williams R., Tuomilehto J., and Bailey C. Type 2 diabetes and the metabolic syndrome in Europe. Eur Heart J 7 Suppl. D (2005) 3-5
23. Narin F., Atabek M.E., Karakukcu M., Narin N., Kurtoglu S., Gumus H., et al. The association of plasma homocysteine levels with serum leptin and apolipoprotein B levels in childhood obesity. Ann Saudi Med 25 (2005) 209-214
24. Friso S., Jacques P.F., Wilson P.W., Rosenberg I.H., and Selhub J. Low circulating vitamin B(6) is associated with elevation of the inflammation marker C-reactive protein independently of plasma homocysteine levels. Circulation 103 (2001) 2788-2791
25. Rohde L.E., Hennekens C.H., and Ridker P.M. Survey of C-reactive protein and cardiovascular risk factors in apparently healthy men. Am J Cardiol 84 (1999) 1018-1022
26. Holven K.B., Aukrust P., Retterstol K., Hagve T.A., Morkrid L., Ose L., et al. Increased levels of C-reactive protein and interleukin-6 in hyperhomocysteinemic subjects. Scand J Clin Lab Invest 66 (2006) 45-54
27. Aso Y., Yoshida N., Okumura K., Wakabayashi S., Matsutomo R., Takebayashi K., et al. Coagulation and inflammation in overt diabetic nephropathy: association with hyperhomocysteinemia. Clin Chim Acta 348 (2004) 139-145
28. Shai I., Stampfer M.J., Ma J., Manson J.E., Hankinson S.E., Cannuscio C., et al. Homocysteine as a risk factor for coronary heart diseases and its association with inflammatory biomarkers, lipids and dietary factors. Atherosclerosis 177 (2004) 375-381
29. Hofmann M.A., Lalla E., Lu Y., Gleason M.R., Wolf B.M., Tanji N., et al. Hyperhomocysteinemia enhances vascular inflammation and accelerates atherosclerosis in a murine model. J Clin Invest 107 (2001) 675-683
30. Holven K.B., Scholz H., Halvorsen B., Aukrust P., Ose L., and Nenseter M.S. Hyperhomocysteinemic subjects have enhanced expression of lectin-like oxidized LDL receptor-1 in mononuclear cells. J Nutr 133 (2003) 3588-3591
31. Lee H., Kim J.M., Kim H.J., Lee I., and Chang N. Folic acid supplementation can reduce the endothelial damage in rat brain microvasculature due to hyperhomocysteinemia. J Nutr 135 (2005) 544-548
32. Jakubowski H. Pathophysiological consequences of homocysteine excess. J Nutr 136 (2006) 1741S-1749S
33. Chwatko G., and Jakubowski H. The determination of homocysteine-thiolactone in human plasma. Anal Biochem 337 2 (2005) 271-277
34. Chwatko G., Boers G.H., Strauss K.A., Shih D.M., and Jakubowski H. Mutations in methylenetetrahydrofolate reductase or cystathionine beta-synthase gene, or a high-methionine diet, increase homocysteine thiolactone levels in humans and mice. FASEB J 21 (2007) 1707-1713
35. Jakubowski H. Metabolism of homocysteine thiolactone in human cell cultures: possible mechanism for pathological consequences of elevated homocysteine levels. J Biol Chem 272 (1997) 1935-1942
36. Jakubowski H. Protein N-homocysteinylation: implications for atherosclerosis. Biomed Pharmacother 55 (2001) 443-447
37. Jakubowski H. Homocysteine is a protein amino acid in humans: implications for homocysteine-linked disease. J Biol Chem 277 (2002) 30425-30428
38. Naruszewicz M., Olszewski A.J., Mirkiewicz E., and McCully K.S. Thiolation of low-density lipoprotein by homocysteine thiolactone causes increased aggregation and altered interaction with cultured macrophages. Nutr Metab Cardiovasc Dis 4 (1994) 70-77
39. Ferretti G., Bacchetti T., Moroni C., Vignini A., Nanetti L., and Curatola G. Effect of homocysteinylation of low density lipoproteins on lipid peroxidation of human endothelial cells. J Cell Biochem 92 (2004) 351-360
40. Undas A., Perla J., Lacinski M., Trzeciak W., Kazmierski R., and Jakubowski H. Autoantibodies against N-homocysteinylated proteins in humans: implications for atherosclerosis. Stroke 35 (2004) 1299-1304